Connection

Yazdan Yazdanpanah to Emtricitabine

Back to Details
This is a "connection" page, showing publications Yazdan Yazdanpanah has written about Emtricitabine.
Yazdan Yazdanpanah
Connection Strength
0.318
Emtricitabine
  1. Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial. Lancet HIV. 2017 11; 4(11):e486-e494.
    View in: PubMed
    Score: 0.161
  2. Switch as maintenance to elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate: week 48 results in a clinical cohort. J Antimicrob Chemother. 2017 06 01; 72(6):1745-1751.
    View in: PubMed
    Score: 0.158
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.